The hormone-stimulated 'dense-vesicle' cyclic AMP phosphodiesterase was solubilized as a proteolytically 'clipped' species, and purified to apparent homogeneity from rat liver with a 2000-3000-fold purification and a 13-18% yield. It appeared to be a dimer (Mr 112000), of two Mr-57000 subunits. Solubilization of either a liver or a hepatocyte membrane fraction, with sodium cholate in the presence of the protein inhibitor benzamidine, identified three protein bands which could be immunoprecipitated by a polyclonal antibody raised against the pure enzyme. The major band at Mr 62000 is suggested to be the native 'dense-vesicle' enzyme, having a Mr5000 extension which serves to anchor this enzyme to the membrane and which is cleaved off during proteolytic solubilization; the Mr-200000 band is an aggregate of the Mr-62000 species, and the Mr-63000 species is possibly a precursor. The purified 'clipped' enzyme hydrolysed cyclic AMP with kinetics indicative of apparent negative co-operativity, with a Hill coefficient inotropic effects on the heart, was extremely theromolabile, with a half-life of 4.5 + 0.5 min at 40°C, and was shown to be distinct from the rat liver insulin-stimulated peripheral-plasma-membrane cyclic AMP phosphodiesterase [Marchmont, Ayad & Houslay (1981) Biochem. J. 195,[645][646][647][648][649][650][651][652].
INTRODUCTION
It has been shown ) that insulin can stimulate the activity of at least three distinct cyclic AMP phosphodiesterases in hepatocytes, two of which are membrane-bound. One is the highaffinity peripheral-plasma-membrane phosphodiesterase (Marchmont & Houslay, 1980a,b; _Marchmont et al., 1981) , which is activated solely by insulin, and the other is the so-called 'dense-vesicle' enzyme, which can be activated by both insulin and glucagon (Loten et al., 1978 (Loten et al., , 1980 Heyworth et al., 1983; Houslay et al., 1983) . The mechanism whereby glucagon activates the 'dense-vesicle' enzyme is distinct from that employed by insulin and is mediated by cyclic AMP . Insulin, however, activates the 'dense-vesicle' and plasma-membrane phosphodiesterases by completely distinct routes Heyworth et al., 1983 Heyworth et al., , 1986 .
The 'dense-vesicle' enzyme is an integral membrane protein which can be released from its membrane environment by the 'hypotonic shock' procedure developed by Loten et al. (1978) , and which is believed (Loten et al., 1980) to result from the action of endogenous proteinases. This procedure liberates an active, soluble and proteolytically 'clipped' enzyme which still reflects any activation elicited by either insulin or glucagon treatment of liver or hepatocytes (Loten et al., 1978) .
Release of a spectrum of phosphodiesterases has hindered purification of the detergent-solubilized enzyme (Loten, 1983; Francis & Kono, 1982) . We have taken advantage of the ability to release an identifiably hormone-activated enzyme to purify the proteolytically 'clipped' solubilized form of the 'dense-vesicle' cyclic AMP phosphodiesterase to apparent homogeneity, by two different purification procedures. This ' dense-vesicle' enzyme is shown to be quite distinct from the insulin-stimulated plasma-membrane cyclic AMP phosphodiesterase.
MATERIALS AND METHODS
All radiochemicals (1251, cyclic [3H]AMP and cyclic [3H]GMP) were from Amersham International, Amersham, Bucks., U.K. All biochemicals, including dipyridamole (see Weishaar et al., 1985) , unless stated otherwise, were from Sigma, Poole, Dorset, U.K. Cyclic AMP and cyclic GMP were from Boehringer Corp. (U.K.), Lewes, East Sussex, U.K. DEAE-cellulose DE-52 and ECTEOLA-cellulose were from Whatman Biochemicals, Maidstone, Kent, U.K. Sepharose CL6B, DEAE-Sepharose 6B, Sephacryl S-200, aminopentylagarose and CNBr-activated Sepharose 6B were from Pharmacia Fine Chemicals, Uppsala, Sweden. Affi-gel Blue was from Bio-Rad, Watford, Herts., U.K. Immunoprecipitin was from Gibco-BRL Chemicals, Paisley, Vol. 242 Abbreviations used: PAGE, polyacrylamide-gel electrophoresis; PMSF, phenylmethanesulphonyl fluoride. Scotland, U.K. ICI 63197 (2-amino-6-methyl-5-oxo-4-n-propyl-4,5-dihydro-S-triazolo[1,5-a]pyrimidine) was kindly given by ICI Pharmaceuticals, Macclesfield, Cheshire, U.K. (see Davies, 1973) . Amrinone and milrinone (see Bristol et al., 1984) were kindly given by Sterling Winthrop, Guildford, Surrey, U.K. RO-1724 [DL-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone] was kindly given by Roche Products, Welwyn Garden City, Herts., U.K. Buquineran (UK 14, 275) and Carbazeran (UK 31, 557) were kindly given by Pfizer Central Research, Sandwich, Kent, U.K. (see Bristol & Evans, 1983) . SQ-20009 was from Squibb Pharmaceuticals (see Hwang & Szentivaryi, 1979) .
Cyclic AMP phosphodiesterase activity was assessed by a modification of the two-step procedure of Thompson & Appleman (1971) as described in detail by us previously (Marchmont & Houslay, 1980b SDS/PAGE and 'non-denaturing' PAGE, with subsequent elution of enzyme activity, and the determination of Mr-were performed as described by Marchmont & Houslay (1980b) .
Protein concentrations were determined with a Bio-Rad protein assay kit (Bradford, 1976; Spector, 1978) for the solubilized enzyme and by a modification of the micro-biuret method (Goa, 1953) Takemoto et al. (1982) . Briefly, a sample of protein (2-10,g) was freeze-dried and rehydrated in 1 MTris/HCI (pH 7.5)/8% SDS before addition of 1251 (100-500 ptCi) and chloramine-T (0.4 mg/ml) in a total volume of 40,u. After 1 min at room temperature the reaction was terminated with 40 1l of 0.1 M-Tris/HCl, pH 7.0, containing 2% SDS and 2% ,-mercaptoethanol, and the samples were boiled for 2 min. After cooling, the solution was made 0.100 Bromophenol Blue/10%o glycerol final concentration, before SDS/PAGE. Twodimensional chromatographic analysis of tryptic peptides of the 125I-labelled enzyme was performed as described by Takemoto et al. (1982) . Preparation of the immune serum
The 'dense-vesicle' phosphodiesterase was purified to apparent homogeneity and used as the immunogen. The immunization procedure involved combining an equal volume of immunogen with Freund's complete adjuvant before injecting it (intra-muscularly) into an adult rabbit. Injections were repeated over a period of 3 months with incomplete adjuvant. The immune serum was obtained by bleeding the animal and collecting 30 ml of blood each time. Collected blood was left at 4°C for 2 h to allow the formation of a clot, which was subsequently removed and the plasma centrifuged at 15000 ga,v for 15 min at 4 'C. To the supernatant was added 20 g (wet wt.) of DEAE-cellulose, which had been pre-equilibrated with 10 mM-KH2PO4/K2HPO4 (equilibrating) buffer, pH 7.5. This was left at 4 'C for 30 min with occasional stirring. The DEAE-cellulose was then removed by filtration. The filtrate was diluted in equilibrating buffer (1:1, v/v) before addition of solid (NH4)2SO4 to 45% saturation, with stirring. After gentle stirring (15 min, 4°C) it was centrifuged for 15 min at 15000 gv.. The pellet was resuspended in equilibrating buffer (5 ml) and dialysed against two changes of 2 litres of equilibrating buffer before being divided into portions for freeze-drying or storage at -70 'C.
Preparation of hepatocyte extracts for immunoprecipitation
Hepatocytes were prepared, preincubated and incubated as described in some detail by us previously . Cells were harvested by centrifugation at 400 rev./min in an MSE Minor centrifuge for 2 min at 4 'C and then resuspended in 3 ml of ice-cold 0.25 M-sucrose containing 10 mM-Tris/HCl, final pH 7.4, 0.1 mM-PMSF, 2 mM-benzamidine and 1 mM-EDTA. Disruption of the cells was achieved by 30 up-and-down strokes of a Teflon pestle in glass homogenizer (Camlab), and the homogenate was centrifuged at 18 000 ga, for 15 min at 4 'C. The resultant pellet was treated in one of two ways.
(i) 'Hypotonic shock treatment', by resuspending it in 1 mM-EDTA/l0 mM-Tris/HCl, pH 7.4, and leaving it at 4 'C for 30 min before centrifugation as above. The supernatant was freeze-dried and iodinated as above, but with omission of SDS, and then taken for immunoprecipitation.
(ii) Resuspension in 0.25 M-sucrose containing 10 mMTris/HCl, pH 7.4, 1 mM-EDTA, 0.1 mM-PMSF, 2 mmbenzamidine and 1 % sodium cholate and leaving it at 4 'C for 45 min. Centrifugation was performed as above and the supernatant dialysed against 2 litres of 0.25 M-sucrose/10 mM Tris/HCl (pH 7.4)/1 mM-EDTA/ 2 mM-benzamidine/0.2 mM-PMSF before freeze-drying and iodination again with the omission of SDS. Iodinated samples were then taken for immunoprecipitation reactions.
Immunoprecipitation
Iodinated samples from the above procedures were resuspended in 0.8 ml of 10 mM KH2PO4/K2HPO4 buffer, final pH 7.4, containing 0.90% NaCl. To this was added 200,l of Mixture A, containing (final concns.) 50 mM-Tris/HCl, pH 7.4, 1 % (w/v) Triton X-100, 1 % (w/v) sodium deoxycholate, 0.1 % (w/v) SDS, 1 mM-EDTA, 0.15 M-NaCl, and 25 g1 of 2% (w/v) gelatin. This was then incubated for 1 h at 30°C before Immunoprecipitin (25 1l; 10%, w/v) was added and incubated for 15 min at 30°C before centrifugation at 14000 gayv for 1 min. The pellet was washed once with Mixture A alone, twice with Mixture A containing 0.5 M-NaCl and twice with 10 mM-Tris/HCl, final pH 7.4. The pellet was added to 100 ,1 of electrophoresis sample buffer (Laemmli, 1970) , and boiled for 2 min before SDS/PAGE.
Single-dimension analysis of tryptic peptides derived from immunoprecipitated 1251-labelled proteins separated on SDS/PAGE, as above, was performed by a modification of the method of Cleveland et al. (1977) . Briefly, after location of proteins by autoradiography, radioactive bands of gel were excised and re-hydrated at room temperature for 30 min in 0.10% SDS in 0.125 MTris/HCl buffer, pH 6.7. The gel chip was then mixed with 40 #1 of 0.01 % Bromophenol Blue, 10% glycerol and 0.125 M-Tris/HCl buffer, pH 6.7, containing 200 ng of trypsin. This was loaded on a 15 % -acrylamide gel with a 5% stacking gel and, after the dye front was about to enter the main gel, power was switched off for 30 min, before the run was continued to completion. The dried gel was subjected to autoradiography and the X-ray film scanned with a Bio-Rad model 620 gel scanner operated by an Olivetti M21 microcomputer. Purification of the 'dense-vesicle' cyclic AMP phosphodiesterase Method 1.
Step 1: solubilization of cyclic AMP phosphodiesterase from rat liver as described above.
Step 2: ECTEOLA-cellulose chromatography. A column (20 cm x 2 cm) of ECTEOLA-cellulose was equilibrated in buffer A, containing 10 mM-Tris/HCl, pH 7.4, 1 mM-MgCI2, 2 mM-benzamidine and 0.1 mM-PMSF. The hypo-osmotic extract (60 ml) was applied at a flow rate of 0.5 ml/min. The column was then washed with buffer A until no further protein (A280) was eluted, and then with 100 ml of buffer A containing 0.15 M-NaCl and 20% ethylene glycol or until no further protein (A280) was eluted. The bound 'dense-vesicle' phosphodiesterase was then eluted with buffer A containing 0.4 M-NaCl and 20% ethylene glycol. Fractions (3 ml) containing the highest specific activity (pmol/min per mg) were pooled.
Step 3: hydrophobic chromatography. The fractions were diluted 1:1 (v/v) with buffer A before application to a column (5 cm x 1 cm) of aminopentyl-agarose that had been previously equilibrated with buffer A at a flow rate of 0.4 ml/min. The column was then extensively washed with 40 ml of buffer A or until no further protein was eluted. It was then washed with buffer A containing 0.275 M-NaCl and 20% ethylene glycol (100 ml) until A280 was constant. The 'dense-vesicle' cyclic AMP phosphodiesterase activity was eluted with buffer A containing 0.5 M-NaCl and 20% ethylene glycol. Fractions (3 ml) containing the highest specific activity were pooled; the NaCl was removed by gel filtration on a Sephadex G-25 column equilibrated in buffer A.
Step 4: guanine-Sepharose chromatography. Guanine-Sepharose, prepared as in Whitson & Appleman (1982) , was pre-equilibrated in buffer A before use.
Fractions from the previous step were applied (flow rate 0.1I ml/min) to a column (3 cm x 0.3 cm) of guanineSepharose. It was then washed with buffer A until no
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further protein was eluted. The 'dense-vesicle' phosphodiesterase was eluted with buffer A containing 0.4 M-NaCl and 20% ethylene glycol. Fractions (1 ml) of the highest specific activity were pooled.
Method 2.
Step 1: solubilization of cyclic AMP phosphodiesterase. This was as described above.
Step 2: two-step Affi-g6l Blue procedure. The 'hypotonic-shock' extract waW adjusted to 10 mM-MgCl2 and applied to a column (5 cm x 1 cm) of Affi-gel Blue which had previously been equilibrated in buffer B. Buffer B contained 2 mM-benzamidine, 0.1 mM-PMSF, 5 mM-MgCl2, 2 mM-/?-mercaptoethanol and 10 mMTris/HCl, final pH 7.4. The column was washed with buffer B until no further protein (A280) was eluted. The 'dense-vesicle' phosphodiesterase activity was eluted with buffer B containing 1 mM-EDTA in place of 5 mM-MgC12, and fractions (3 ml) containing the highest specific activity were pooled. These were adjusted to 10 mM-MgCl2 and applied to a second Affi-gel Blue column (1 cm x 1 cm) previously equilibrated with buffer B. The column was washed with buffer B, continuing with 30-50 ml of buffer B after constant A280 was achieved (zero protein). Such a thorough washing was found to be essential to ensure the complete purity of this enzyme species. The 'dense-vesicle' cyclic AMP phosphodiesterase activity was then eluted with buffer B containing 1 mM-cyclic AMP and collected as a single fraction (30 ml).
Step 3: removal of cyclic AMP. DEAE-Sepharose CL6B was pre-equilibrated in 10 mM-Tris/HCl, final pH 7.4, with 5 mM-MgCl2 and 2 mM-/-mercaptoethanol before application of the fraction (flow rate 0.3 ml/min). The column was washed with equilibrating buffer containing 0.1 M-NaCl until A280 was zero, before enzyme elution with equilibrating buffer containing 0.3 M-NaCl and 2 mM-/J-mercaptoethanol. Fractions (3 ml) containing the highest specific activity were pooled.
Enzyme fractions were stored routinely at -70 'C. The cyclic AMP phosphodiesterase activity was stable for 3-4 weeks when the protein concentration was of the order of 5, g/ml and the buffer composition was 5 mM-MgCl2 (with or without ,-mercaptoethanol) and 10 mM-Tris/HCl, final pH 7.4.
The cytosolic and membrane-bound forms of the cyclic GMP-activated cyclic nucleotide phosphodiesterase and the peripheral-plasma-membrane insulinstimulated cyclic AMP phosphodiesterase were purified to apparent homogeneity as described previously by us, as was the preparation of a polyclonal antibody to the latter enzyme Houslay et al., 1986) .
RESULTS
'Hypo-osmotic shock' treatment of either a rat liver particulate fraction or a hepatocyte 'high-speed' pellet released some 55% of the total cyclic AMP phosphodiesterase activity associated with this fraction when assessed at 0.1 M-cyclic AMP. Sucrose-density-gradient analysis of this 'solubilized' activity revealed three peaks, with sedimentation coefficients (S20,W) of 3.9 + 0.2 S, 5.4+0.15 S and 7.2+0.37 S (Fig. 1) , the major activity being associated with the 5.4 S fraction, with minor peaks at 7.4 S and 3.9 S (Fig. 1) . If these assays were performed with added unlabelled cyclic GMP (2 ,sM), Sucrose-density-gradient centrifugation of the 'hypotonicshock' released supernatant was performed as described previously by us (Marchmont & Houslay, 1980a; Heyworth et al., 1983 then cyclic AMP hydrolysis by the 5.4 S species was potently inhibited. However, hydrolysis of cyclic AMP by the 7.2 S form was activated 2-3-fold at 0.1 tM-cyclic GMP, and that by the 3.9 S form was relatively unaffected. If hepatocytes were pretreated with insulin (10 nM) for 5 min, glucagon (10 nM) for 5 min, or glucagon (10 nM) for 10 min followed by insulin (10 nM) for 5 min (Fig. 1) , the cyclic AMP phosphodiesterase activity of the major activity peak only (at 5.4 S) was increased, as noted previously . Treatment of hepatocytes with insulin plus glucagon increased solely the activity of the major cyclic AMP phosphodiesterase peak (RF 0.48) seen on non-denaturing PAGE. Such an activity was also inhibited by cyclic GMP (results not shown).
Assayed at 0.1I /M-cyclic AMP, cyclic GMP (2 ,M) almost completely (> 95%) inhibited the cyclic AMP phosphodiesterase activity of the purified 'dense-vesicle' enzyme. Under such conditions 2/Cms unlabelled cyclic GMP elicited 49% inhibition of the cyclic AMP phosphodiesterase activity (41 pmol/min per mg of protein) exhibited by a 'hypotonic shock' extract of hepatocyte membranes. However, ifcells were pre-treated with insulin (10 nM) for 5 min, in order to activate this enzyme (34%; 55 pmol/min per mg of protein), inhibition by cyclic GMP was increased, to some 60%. This increase in the degree of inhibition would be expected if insulin solely caused the increase in activity of such a 'cyclic GMP-inhibited' enzyme. Assuming that this insulin-stimulated enzyme is similarly (totally) inhibited by cyclic GMP to the native enzyme under these conditions, one can predict that a 62% inhibition should have been observed in this experiment. That a value close to this was observed provides further support for our contention that the hormone-regulated and high-cyclic GMP-inhibited cyclic AMP phosphodiesterase activities are one and the same. Furthermore, an immobilized preparation of the polyclonal antibody (DV1) immunoprecipitated this insulin-activated component (results not shown).
By purification Method 1 the 'dense-vesicle' cyclic AMP phosphodiesterase, released by the 'hypotonicshock' procedure, was purified to apparent homogeneity with an 18% yield and a 2773-fold purification over the specific activity of the original homogenate (Table 1 ; Fig.  2 ). By Method 2 the 'dense-vesicle' enzyme was purified to apparent homogeneity with a 13 % yield and a 2142-fold purification over the specific activity of the homogenate (Table 1 ; Fig. 2 ). The properties of the enzyme purified by both methods appeared to be identical on all occasions. The criteria taken for purification of this species were that hydrolysis of cyclic AMP (0.1 tM) was potently inhibited by 2 /M-cyclic GMP, that the species exhibited a sedimentation coefficient of 5.4 S on sucrose density gradients, and that material taken from (insulin plus glucagon)-treated hepatocytes showed enhanced (180-200% ) activity in the appropriate fractions.
Sucrose-density-gradient analysis of the purified 'dense-vesicle' cyclic AMP phosphodiesterase from both procedures yielded a single symmetrical peak (S20,W= 5.2+0.15 S) of cyclic AMP phosphodiesterase activity (0.1 ,UM substrate). A Mr of approx. 100000 can be deduced from this result, in accord with estimations of a Mr of 112000 + 4000 by Sephacryl S200 gel-exclusion chromatography. Both procedures provided a preparation showing a single protein band on 'non-denaturing/ dissociating' PAGE, which migrated with an RF value of 0.48 + 0.20 and which co-migrated with the single peak of phosphodiesterase activity eluted from the gel (Fig. 3) . A subunit Mr of 57 000 (Fig. 3) was obtained by SDS/PAGE, suggesting that this enzyme is a dimer of two subunits of apparently identical molecular mass. Both procedures yielded an apparently homogeneous enzyme preparation. However, if after the hypo-osmotic solubilization procedure purification was carried out in the absence of proteinase inhibitors, a minor protein band of Mr 51000 was also found together with that of Mr 57000. Two-dimensional mapping of 125I-labelled tryptic peptides of the purified (57000Mr subunit) 'densevesicle' enzyme were performed (Fig. 4a) . That of the 51 OOO-Mr species found when proteinase inhibitors were omitted was very similar (results not shown).
The purified 'dense-vesicle' phosphodiesterase hydrolysed cyclic AMP with kinetics indicative of apparent negative co-operativity (Fig. 5) The polyclonal antibody DV1 both immunoprecipitated the purified 'dense-vesicle' cyclic AMP phosphodiesterase and recognized it in Western (immuno-) blotting (Fig. 6) the cytosol or membrane-bound forms of the rat liver cyclic GMP-stimulated cyclic nucleotide phosphodiesterase or the peripheral-plasma-membrane insulinstimulated cyclic AMP phosphodiesterase (Table 3 ). In addition, a polyclonal antibody raised against the latter enzyme showed no cross-reactivity with the purified 'dense-vesicle' enzyme (Table 3) .
SDS/PAGE of the immunoprecipitated [125I]iodinated purified 'dense-vesicle' enzyme revealed a single species of Mr 57000. The proteinase inhibitor benzamidine blocks the release of the 'dense-vesicle' enzyme from membrane fractions by endogenous proteinases (Loten et al., 1980) . The presumed 'native ' ' unclipped' enzyme can be detergent-solubilized by sodium cholate treatment of liver membranes in the presence of benzamidine and PMSF. Treatment of the detergent-solubilized extract of [1251]iodinated membranes with the antibody DV1 led to immunoprecipitation of radioactive material, which yielded three bands on SDS/PAGE. The major band evident in all preparations had an Mr of 62000.
Comparison of this species with the purified 'clipped' enzyme, which had been 1251-labelled in the absence of SDS, by single-dimension tryptic-peptide mapping (Fig.  4b) , showed them to be very similar indeed (approx. 80 % co-relation), indicating that the Mr-62 000 protein was the 'native' species. There was, however, a minor band migrating just above this, which had an Mr of about 63000 and an intensity at least one-quarter less of that of the band migrating at 62000. This band may reflect a precursor species possessing a signal peptide. The Step 4 Step 2 observed on Western blotting of SDS/PAGE-separated proteins of the entire particulate fraction. In such instances only the Mr-62000 and -63000 species were observed. Western-blot analysis of hepatocytes subjected to SDS/PAGE gave identical results, indicating that the Mr-62000 species was the 'native' form (results not shown).
Sodium cholate solubilization, in the presence of benzamidine and PMSF, of radioiodinated membranes which had been previously been 'hypotonic-shock '-treated to release the 'dense-vesicle' enzyme yielded no material that could be immunoprecipitated by the antibody DV1. The 'hypotonic-shock'-solubilized material, however, gave on immunoprecipitation a single band at Mr 57000 (Fig. 6 ).
DISCUSSION
Exposure of hepatocytes to either insulin or glucagon causes the activation of membrane-bound high-affinity cyclic AMP phosphodiesterase activity [for reviews see Vol. 242 Table 2 . Properties of the 'dense-vesicle' cyclic AMP phosphodiesterase compared with those of the insulin-stimulated cyclic AMP phosphodiesterase and the cytosolic cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver Mr, subunit Mr and the kinetics of cyclic AMP and cyclic GMP hydrolysis for the peripheral-plasma-membrane and cyclic GMP-stimulated plasma-membrane enzyme were taken from Marchmont et al. (1981) and Pyne et al. (1986) Thompson & Strada (1978) , Beavo et al. (1982 ), Francis & Kono (1982 ]. In hepatocytes, insulin increased the phosphodiesterase activity in both the plasma membrane and so-called 'dense-vesicle' fraction, whereas glucagon only activated the 'dense-vesicle' enzyme . The 'dense-vesicle' enzyme cannot be extracted by highionic-strength treatment , but, unlike the plasma-membrane enzyme (Marchmont & Houslay, 1980a,b; Heyworth et al., 1983) , can be released when membranes are put into hypo-osmotic buffer (Loten et al., 1978) . This 'hypotonic shock' procedure appears to involve the proteolytic 'clipping' of the enzyme, solubilizing it in an active form still able to reflect activation elicited by hormones. We have exploited the 'hypotonic shock' method of releasing, in a soluble form, an identifiably insulinand/or glucagon-activated high-affinity cyclic AMP phosphodiesterase in order to purify this enzyme to apparent homogeneity. This enzyme is clearly very different from the plasma-membrane insulin-stimulated species (Marchmont et al., 1981) and cyclic GMPactivated species , isolated from liver, as regards molecular size, kinetics of hydrolysis of both cyclic AMP and cyclic GMP, sensitivity to a variety of phosphodiesterase inhibitors (Table 2) , and the high potency of cyclic GMP to inhibit cyclic AMP hydrolysis by the 'dense-vesicle' enzyme. Indeed, a number of agents known to exert potent positive inotropic effects on the heart, e.g. amrinone, milrinone, carbazeran and buquineran (see Bristol & Evans, 1983; Farah et al., 1984) were found to be potent and selective inhibitors of this enzyme (Table 2) . It is therefore possible that the uncharacterized cardiac 'fraction III' phosphodiesterase, which is purported to be the site of action of such drugs (Endoh et al., 1982; Kariya et al., 1982; Weishaar et al., 1985) , may be similar to the 'dense-vesicle' enzyme that we have isolated here.
It has been suggested (Major et al., 1983 ) that the 'dense-vesicle' and insulin-stimulated peripheral plasmamembrane phosphodiesterases might be related to each other. However, the very different ways by which insulin activates these two enzymes , their different molecular sizes, kinetics, inhibition by selective inhibitors, lack of immunological cross-reactivity, little co-relation of iodinated [1251I]tryptic peptides (less than 20%, Fig. 4 ; see also Takemoto et al., 1982) and differences in their subcellular localization and attachment to membranes suggest strongly that they are distinct enzyme species.
Both purification procedures yielded a protein of Mr 112000, with subunit Mr 57000. Thus the solubilized proteolytically 'clipped' enzyme appears to be a dimer consisting of two subunits of similar size. The polyclonal antibody (DV1) raised against the 'dense-vesicle' enzyme clearly identified the Mr-57000 species on Western blotting of a purified enzyme preparation (Fig. 6) (Kenny & Booth, 1978) . During the preparation of the present paper, the purification of the equivalent insulin-stimulated 'dense-vesicle' enzyme from adipocytes (see Houslay et al., 1983) was reported (Saltiel & Steigerwalt, 1986) . SDS/PAGE of the purified proteolytically clipped preparation yielded a subunit of Mr 60000, with the enzyme forming a dimer as reported here for the liver species.
It is clear from the present and other (Cercek & Houslay, 1982; Houslay et al., 1983; Pyne et al., 1986) Heyworth et al., 1983 Heyworth et al., , 1984 Houslay et al., 1983; Wallace et al., 1984; Houslay, 1986) 
